Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)

Principal Investigators

Contact: Behnam Sabayan
Clinical Neuroscience-Cerebrovascular Changes in Ageing and Dementia
Northwestern University
behnam.sabayan@northwestern.edu

Summary

Countries	Scotland, Ireland, Netherlands
Principal Investigator	PROSPER study group
Contact person (email)	behnam.sabayan@northwestern.edul
Key publication/reference	Shepherd et al. Lancet (2002)
Years in which study conducted	1997-2001
Sample	
Size	5804 (649 with history of stroke/TIA)
Population: Hospital/community	
Selection: consecutive/random	Selected based on a history of, or risk factors for, vascular disease
Admit with previous stroke or TIA	Yes: n=649 (321 placebo, 328 Pravastatin)
Admit with TIA?	Yes
Age range	70–82 years
Number of centres	3
Control group: number, population, selection	Yes: Randomised controlled trial
Assessment	
Initial: Time and data collected/tests administered	Baseline, 9m, 18m, 30m, end of study

Detailed	
Subsequent (follow-ups)	Up to 3.2 y (mean)
Stroke-related data	---
Functional tests/data	ADLs and IADLs
Other medical tests/data	CV risk factors, blood analysis, genotyping, medication and metabolic data
Neuropsychological tests	MMSE and test battery
MRI scans, when and how many	Baseline and at the end of trial (n=553)
PET scans	No
Psychiatric exams/diagnoses	GDS (subset)
Intervention trialled?	Pravastatin

CT=computed tomography scan, MedHx=medical history, VRF=vascular risk factors (hypertension, diabetes, atrial fibrillation, obesity, smoking etc.), NΨ=neuropsychological, TIA=transient ischemic attack, m=month, y=year